At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MIRM Mirum Pharmaceuticals, Inc.
Pre-Mkt 10-23 04:50:26 EDT
83.10
-0.34
-0.41%
盘前83.10
+0.000.00%
04:21 EDT
High84.86Low82.58Vol420.91K
Open83.26D1 Closing83.44Amplitude2.73%
Mkt Cap5.40BTradable Cap4.69BTotal Shares64.93M
T/O34.99MT/O Rate0.75%Tradable Shares56.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mirum Pharmaceuticals Announces Participation in Three Healthcare Investor Conferences
Reuters  ·  10-22 04:01
Mirum Pharmaceuticals Announces Participation in Three Healthcare Investor Conferences
Mirum Pharmaceuticals’ brelovitug receives FDA orphan designation
TIPRANKS  ·  10-22 03:00
Mirum Pharmaceuticals’ brelovitug receives FDA orphan designation
Mirum Pharmaceuticals is Maintained at Buy by Stifel
Dow Jones  ·  10-16
Mirum Pharmaceuticals is Maintained at Buy by Stifel
Mirum Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-16
Mirum Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mirum Pharmaceuticals price target raised to $156 from $136 at Stifel
TIPRANKS  ·  10-15
Mirum Pharmaceuticals price target raised to $156 from $136 at Stifel
Mirum Pharmaceuticals Grants Chief Medical Officer Myers 40,000 Stock Options
Reuters  ·  10-15
Mirum Pharmaceuticals Grants Chief Medical Officer Myers 40,000 Stock Options
Mirum Pharmaceuticals (MIRM) Following Strong EXPAND Data Looks Undervalued But Is It Priced In
Simply Wall St.  ·  10-14
Mirum Pharmaceuticals (MIRM) Following Strong EXPAND Data Looks Undervalued But Is It Priced In
Mirum Pharmaceuticals Price Target Raised to $146.00/Share from $135.00 by Evercore ISI Group
Dow Jones  ·  10-14
Mirum Pharmaceuticals Price Target Raised to $146.00/Share from $135.00 by Evercore ISI Group
Mirum Pharmaceuticals price target raised to $184 from $160 at Citi
TIPRANKS  ·  10-13
Mirum Pharmaceuticals price target raised to $184 from $160 at Citi
Mirum Pharmaceuticals Price Target Raised to $200.00/Share from $195.00 by HC Wainwright & Co.
Dow Jones  ·  10-13
Mirum Pharmaceuticals Price Target Raised to $200.00/Share from $195.00 by HC Wainwright & Co.
Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $200 from $195
THOMSON REUTERS  ·  10-12
Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $200 from $195
Mirum Pharma Shares Gain After Liver-Disease Treatment Meets Primary Endpoint in Phase 3 Trial
Dow Jones  ·  10-12
Mirum Pharma Shares Gain After Liver-Disease Treatment Meets Primary Endpoint in Phase 3 Trial
Mirum Climbs on Positive Late-Stage Trial Results for Liver Disease Drug
Reuters  ·  10-12
Mirum Climbs on Positive Late-Stage Trial Results for Liver Disease Drug
Mirum Pharmaceuticals - Plans U.S. Snda Submission in First Half of 2027 Based on Expand Results
THOMSON REUTERS  ·  10-12
Mirum Pharmaceuticals - Plans U.S. Snda Submission in First Half of 2027 Based on Expand Results
Mirum Pharmaceuticals - Announces Primary Endpoint Met in Phase 3 Expand Study of Livmarli
THOMSON REUTERS  ·  10-12
Mirum Pharmaceuticals - Announces Primary Endpoint Met in Phase 3 Expand Study of Livmarli
Mirum Pharmaceuticals - Maralixibat Demonstrates Statistically Significant Reduction in Pruritus and 69% Reduction in Serum Bile Acids
THOMSON REUTERS  ·  10-12
Mirum Pharmaceuticals - Maralixibat Demonstrates Statistically Significant Reduction in Pruritus and 69% Reduction in Serum Bile Acids
Mirum Pharmaceuticals - Maralixibat Demonstrates Statistically Significant Reduction in Pruritus in Biliary Atresia Patients
THOMSON REUTERS  ·  10-12
Mirum Pharmaceuticals - Maralixibat Demonstrates Statistically Significant Reduction in Pruritus in Biliary Atresia Patients
S&P 500 Futures up in Premarket Trading; Westlake, Core & Main Lead
Dow Jones  ·  10-12
S&P 500 Futures up in Premarket Trading; Westlake, Core & Main Lead
Mirum to Report Phase 3 Expand Topline Data for Livmarli in Ultra-Rare Cholestatic Liver Diseases Oct. 12
Reuters  ·  10-12
Mirum to Report Phase 3 Expand Topline Data for Livmarli in Ultra-Rare Cholestatic Liver Diseases Oct. 12
RBC Raises Price Target on Mirum Pharmaceuticals to $155 From $135, Keeps Outperform Rating
MT Newswires Live  ·  10-08
RBC Raises Price Target on Mirum Pharmaceuticals to $155 From $135, Keeps Outperform Rating

Introduction

Company Name.
Mirum Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Issue price:
--